Ivermectin for COVID-19: real-time analysis of all 89 studies

Covid Analysis (Preprint) (meta analysis)

Ivermectin for COVID-19: real-time meta analysis of 52 studies

• 98% of the 52 studies to date report positive effects (25 statistically significant in isolation). Random effects meta-analysis for early treatment and pooled effects shows an 81% reduction, RR 0.19 [0.09-0.39], and prophylactic use shows 85% improvement, RR 0.15 [0.09-0.25]. Mortality results show 76% lower mortality, RR 0.24 [0.14-0.42] for all treatment delays, and 84% lower, RR 0.16 [0.04-0.63] for early treatment.

• 96% of the 27 Randomized Controlled Trials (RCTs) report positive effects, with an estimated 64% improvement, RR 0.36 [0.24-0.52].

• The probability that an ineffective treatment generated results as positive as the 52 studies to date is estimated to be 1 in 85 trillion (p = 0.000000000000012).

• Heterogeneity arises from many factors including treatment delay, patient population, the effect measured, distribution of SARS-CoV-2 variants, ivermectin dosage, and other treatment details. There is high heterogeneity across all studies, however for ivermectin the consistency of positive results is remarkable. Heterogeneity is low when looking at specific cases, for example early treatment mortality.

• All data to reproduce this paper and the sources are in the appendix. See [Bryant, Hill, Kory, Lawrie, Nardelli] for other meta analyses, all with similar results confirming effectiveness.

	Improvement	Studies	Authors	Patients
Early treatment	81% [61‑91%]	18	175	1,937
Late treatment	43% [27‑56%]	20	143	6,831
Prophylaxis	85% [75‑91%]	14	108	8,789
Mortality	76% [58‑86%]	18	155	7,267
RCTs only	64% [48‑76%]	27	246	4,849
All studies	72% [64‑78%]	52	426	17,557

Evidence base used for other COVID-19 approvals
Medication	Studies	Patients	Improvement
Remdesivir (USA)	1	1,063	31%
Casiri/imdevimab (USA)	1	799	66%
Budesonide (UK)	1	1,779	17%
Ivermectin evidence	52	17,557	72% [64‑78%]

[1] fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-autho..

[2] fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-anti..

[3] england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/04/C1253-interim-position-statement-in..

DiNicolantonio et al., Open Heart, doi:10.1136/openhrt-2021-001655 (Review) (Peer Reviewed)

Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors

Review suggesting that the effectiveness of ivermectin in the cytokine storm phase of COVID-19 may be, at least in part, an anti-inflammatory effect mediated by increased activation of glycine receptors on leukocytes and possibly vascular endothelium.

DiNicolantonio et al., 4/19/2021, peer-reviewed, 3 authors.

Morgenstern et al., medRxiv, doi:10.1101/2021.04.10.21255248 (Preprint)

Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylactic method in Healthcare Workers

Propensity matched retrospective prophylaxis study of healthcare workers in the Dominican Republic showing significantly lower cases with treatment, and no hospitalization with treatment (versus 2 in the PSM matched control group). The cases with treatment were mostly in the first week, with only one case in the second and third weeks, and none in the fourth week. NCT04832945.

risk of hospitalization, 80.0% lower, RR 0.20, p = 0.50, treatment 0 of 271 (0.0%), control 2 of 271 (0.7%), continuity correction due to zero event, PSM.

risk of COVID-19 case, 74.0% lower, RR 0.26, p = 0.008, treatment 5 of 271 (1.8%), control 18 of 271 (6.6%), adjusted, PSM, multivariate Cox regression.

Morgenstern et al., 4/16/2021, retrospective, Dominican Republic, Caribbean, preprint, 16 authors, dosage 200μg/kg weekly.

Seet et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.04.035 (Peer Reviewed)

Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial

Prophylaxis RCT in Singapore with 3,037 low risk patients, showing lower serious cases, lower symptomatic cases, and lower confirmed cases of COVID-19 with all treatments (ivermectin, HCQ, PVP-I, and Zinc + vitamin C) compared to vitamin C.

The ivermectin dosage was low for 42 days prophylaxis - only a single dose of 200µg/kg, with a maximum of 12mg.

Meta-analysis of vitamin C in 6 previous trials shows a benefit of 16%, so the actual benefit of ivermectin, HCQ, and PVP-I may be higher. Cluster RCT with 40 clusters.

There were no hospitalizations and no deaths. NCT04446104.

risk of COVID-19 severe case, 49.8% lower, RR 0.50, p = 0.01, treatment 32 of 617 (5.2%), control 64 of 619 (10.3%).

risk of COVID-19 case, 5.8% lower, RR 0.94, p = 0.61, treatment 398 of 617 (64.5%), control 433 of 619 (70.0%), adjusted, OR converted to RR, model 6.

Seet et al., 4/14/2021, Cluster Randomized Controlled Trial, Singapore, Asia, peer-reviewed, 15 authors, dosage 12mg single dose, 200µg/kg, maximum 12mg, this trial compares with another treatment - results may be better when compared to placebo.

Bello et al., Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.1911857 (Peer Reviewed)

Elucidation of the inhibitory activity of ivermectin with host nuclear importin α and several SARS-CoV-2 targets

In Silico analysis finding that the in vitro activity of ivermectin may explained by acting as an inhibitor of importin-α, dimeric 3CLpro, and Nsp9.

Bello et al., 4/10/2021, peer-reviewed, 1 author.

Turkia, M., Research Gate (Review) (Preprint)

A timeline of ivermectin-related events in the COVID-19 pandemic

An extensive timeline of ivermectin-related events from April 2020 to March 2021 including studies, news, health authority decisions, biased news coverage, and censorship.

The author concludes that in a broader historical perspective, the timeline depicts rather dysfunctional societies unable to properly communicate and organize themselves, leading to misallocation of resources and decisions that may have conflicted with elementary ethical considerations, with this behavior rationalized by claiming adherence to mental paradigms that may have poorly matched the situation.

Turkia et al., 4/3/2021, preprint, 1 author.

Mourya et al., Int. J. Health and Clinical Research (Peer Reviewed)

Comparative Analytical Study of Two Different Drug Regimens in Treatment of Covid 19 Positive Patients in Index Medical College Hospital and Research Center, Indore, India

Retrospective 100 patients in India with 50 treated with ivermectin, and SOC for all patients including HCQ+AZ, showing much higher viral clearance with ivermectin. Baseline clinical status was worse in the control group. Time of testing after treatment initiation was longer in the control group (mean 7.24 days versus 5.22 days).

risk of no virological cure, 89.4% lower, RR 0.11, p < 0.001, treatment 5 of 50 (10.0%), control 47 of 50 (94.0%).

Mourya et al., 4/1/2021, retrospective, India, South Asia, peer-reviewed, 5 authors, dosage 12mg days 1-7.

Chahla et al., medRxiv, doi:10.1101/2021.03.29.21254554 (Preprint)

Ivermectin reproposing for COVID-19 treatment outpatients in mild stage in primary health care centers

Cluster RCT outpatients in Argentina showing signficantly faster recovery with ivermectin. There were no deaths. Cluster RCT where outpatients in Tucumán were assigned to the ivermectin group and outpatients from San Miguel de Tucumán and Gran San Miguel de Tucumán were assigned to the control group. All comorbidities, percentage of male patients, and age were higher in the ivermectin group, favoring the control group. NCT04784481.

risk of no medical release, 89.1% lower, RR 0.11, p = 0.005, treatment 2 of 110 (1.8%), control 8 of 62 (12.9%), adjusted, OR converted to RR.

Chahla et al., 3/30/2021, Cluster Randomized Controlled Trial, Argentina, South America, preprint, 9 authors, dosage 24mg days 1, 8, 15, 22.

Kow et al., Pharmacological Reports, doi:10.1007/s43440-021-00245-z (Peer Reviewed)

The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis

Small meta analysis of 6 RCTs showing mortality OR 0.21 [0.11-0.42]. Authors do not include two more recent RCTs with mortality results, 10 other studies with mortality results, and a total of 42 other studies including other outcomes. Authors do not distinguish between studies with very different treatment delays (earlier treatment is more successful).

Kow et al., 3/29/2021, peer-reviewed, 4 authors.

Tanioka et al., medRxiv, doi:10.1101/2021.03.26.21254377 (Preprint)

Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?

Retrospective study of the 31 onchocerciasis-endemic countries using the community-directed treatment with ivermectin (CDTI) and the 22 non-endemic countries in Africa, showing significantly lower mortality per capita in the countries using ivermectin.

risk of death, 88.2% lower, RR 0.12, p = 0.002, relative mean mortality per million.

Tanioka et al., 3/26/2021, retrospective, ecological study, multiple countries, Africa, preprint, 3 authors, dosage 200μg/kg, dose varied, typically 150-200μg/kg.

Udofia et al., Network Modeling Analysis in Health Informatics and Bioinformatics, doi:10.1007/s13721-021-00299-2 (Peer Reviewed)

In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV

In Silico analysis finding that ivermectin had the highest binding energy against the 3CLpro of SARS-CoV-2 and RdRps of both SARS-CoV and SARS-CoV-2.

Udofia et al., 3/25/2021, peer-reviewed, 5 authors.

Choudhury et al., Future Medicine, doi:10.2217/fvl-2020-0342 (Peer Reviewed)

Exploring the binding efficacy of ivermectin against the key proteins of SARS-CoV-2 pathogenesis: an in silico approach

In Silico analysis finding that ivermectin has high binding affinity for the SARS-CoV-2 viral spike protein, main protease, replicase, and human TMPRSS2 receptors.

Choudhury et al., 3/25/2021, peer-reviewed, 7 authors.

Huvemek Press Release (Preprint)

Kovid-19 - Huvemek® Phase 2 clinical trial

Phase 2 results from a multicenter RCT of hospitalized patients in Bulgaria showing faster viral clearance, greater clinical improvement, and improved biomarkers with treatment. Ivermectin was taken on an empty stomach, potentially reducing lung tissue concentration by ~2.5x [1]. Limited data has been reported currently. No serious adverse events were observed. EudraCT 2020-002091-12.

[1] twitter.com/Covid19Crusher/status/1367854845340844039

risk of no improvement, 31.6% lower, RR 0.68, p = 0.28, treatment 13 of 50 (26.0%), control 19 of 50 (38.0%), day 7, patients with improvement on WHO scale.

risk of no improvement, 34.5% lower, RR 0.66, p = 0.07, treatment 19 of 50 (38.0%), control 29 of 50 (58.0%), day 4, patients with improvement on WHO scale.

Huvemek et al., 3/25/2021, Double Blind Randomized Controlled Trial, Bulgaria, Europe, preprint, 1 author, dosage 400μg/kg days 1-3.

Yagisawa et al., The Japanese Journal of Antibiotics, 74-1, Mar 2021 (Review) (Peer Reviewed)

Global trends in clinical studies of ivermectin in COVID-19

Review of ivermectin for COVID-19. Authors note that Kitasato University's project was expanded in response to the results of Caly et al. which had left questions regarding in vivo therapeutic levels, and the results of those studies were positive. Early in the pandemic, Kitasato University requested Merck to conduct clinical trials in Japan because they have priority for an expansion of ivermectin's indications, however Merck declined.

Since large companies have declined to study ivermectin for COVID-19, trials have been mostly doctor-initiated with relatively little funding. Authors discuss these, noting that the physicians involved are enthusiastic about avoiding bias, and strive to treat and prevent COVID-19 witn non-profit motives.

Authors discuss the trials, epidemiological data, and inaccurate statements made by certain authorities.

Authors note that regulations make it challenging for doctor-initiated trials to enroll many participants in a timely manner.

Authors conclude that ivermectin may turn out to be comparable to the benefits achieved from the discovery of penicillin - said to be one of the greatest discoveries of the twentieth century.

Authors include the nobel prize winning biochemist who discovered ivermectin, Satoshi Ōmura [1].

[1] en.wikipedia.org/wiki/Satoshi_%C5%8Cmura

Yagisawa et al., 3/24/2021, peer-reviewed, 4 authors.

Emmerich et al., Int. J. Environ. Res. Public Health, doi:10.3390/ijerph18073371 (Peer Reviewed)

Comparisons between the Neighboring States of Amazonas and Pará in Brazil in the Second Wave of COVID-19 Outbreak and a Possible Role of Early Ambulatory Treatment

Comparison between the two largest neighboring states in Brazil, Amazonas and Pará, showing more than 5 times lower mortality in Pará during the second wave when the Pará government supported early treatment and Amazonas did not, compared to similar results in the first wave when treatment protocols were similar.

Emmerich et al., 3/21/2021, peer-reviewed, 1 author.

Del Franco et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1008 (Peer Reviewed)

Ivermectin in Long-Covid Patients: A Retrospective Study

Retrospective 856 patients previously admitted to hospital for COVID-19 in Argentina, finding that ivermectin improved recovery from "long covid" symptoms.

Del Franco et al., 3/18/2021, peer-reviewed, 3 authors.

Roy et al., medRxiv, doi:10.1101/2021.03.08.21252883 (Preprint)

Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study

Retrospective database analysis of 56 mild COVID-19 patients, all treated with vitamin C, vitamin D, and zinc, comparing ivermectin + doxycycline (n=14), AZ (n=13), HCQ (n=14), and SOC (n=15), finding that all groups recover quickly, and there was no significant difference between the groups. Subject to the usual limitation of a database study, very small size, and limited evaluation of patients.

relative time to clinical response of wellbeing, 5.6% lower, relative time 0.94, p = 0.87, treatment 14, control 15.

Roy et al., 3/12/2021, retrospective, database analysis, India, South Asia, preprint, 5 authors, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.

Nardelli et al., Signa Vitae, doi:10.22514/sv.2021.043 (Peer Reviewed)

Crying wolf in time of Corona: the strange case of ivermectin and hydroxychloroquine. Is the fear of failure withholding potential life-saving treatment from clinical use?

Meta analysis of RCT mortality results showing RR 0.19, p < 0.00001.

risk of death, 79.5% lower, RR 0.21, p < 0.001, treatment 14 of 703 (2.0%), control 57 of 620 (9.2%), OR converted to RR.

Nardelli et al., 3/11/2021, peer-reviewed, 8 authors.

Scheim et al., OSF Preprints (Preprint)

Ivermectin sales in Valle del Cauca, Colombia, patterns of AEs, and other background re López-Medina et al. 2021

Analysis of several issues with López-Medina et al. including the atypical adverse effects in the control arm and population use of ivermectin.

Scheim et al., 3/11/2021, preprint, 1 author.

Bryant et al., Research Square, doi:10.21203/rs.3.rs-317485/v1 (OSF preprints 3/11) (Preprint)

Ivermectin for prevention and treatment of COVID-19 infection: a systematic review and meta-analysis

Systematic review and meta analysis of 21 RCTs finding mortality RR 0.32 [0.14-0.72], and prophylaxis case RR 0.14 [0.09-0.21].

risk of death, 68.0% lower, RR 0.32, p = 0.006.

risk of COVID-19 case, 86.0% lower, RR 0.14, p < 0.001.

Bryant et al., 3/11/2021, preprint, 7 authors.

Scheim et al., OSF Preprints (Preprint)

Protocol violations in López-Medina et al.: 38 switched ivermectin (IVM) and placebo doses, failure of blinding, widespread IVM sales OTC in Cali, and nearly identical AEs for the IVM and control groups

Report on protocol violations in López-Medina et al.

Scheim et al., 3/11/2021, preprint, 3 authors.

Yesilbag et al., Virus Research, doi:10.1016/j.virusres.2021.198384 (Peer Reviewed) (In Vitro)

Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV) in vitro

In Vitro study showing that ivermectin can inhibit infection of bovine respiratory disease viral agents BCoV, BPIV-3, BVDV, BRSV and BoHV-1 at the concentrations of 2.5 and 5 μM and in a dose-dependent manner.

Yesilbag et al., 3/10/2021, peer-reviewed, 3 authors.

Pott-Junior et al., Toxicology Reports, doi:10.1016/j.toxrep.2021.03.003 (Peer Reviewed)

Use of ivermectin in the treatment of Covid-19: a pilot trial

Small RCT with 4 control patients and 28 ivermectin patients split across 3 different dosage levels, showing lower (non-statistically significant) ICU admission with treatment. Authors suggest that ivermectin for SARS-CoV-2 is safe and reduces symptoms and viral load. They note that ivermectin’s antiviral effect appear to be dose-dependent. NCT04431466.

risk of ICU admission, 85.2% lower, RR 0.15, p = 0.25, treatment 1 of 27 (3.7%), control 1 of 4 (25.0%).

relative improvement in Ct value, 0.8% lower, RR 0.99, p = 1.00, treatment 27, control 3.

risk of no virological cure, 11.1% higher, RR 1.11, p = 1.00, treatment 10 of 27 (37.0%), control 1 of 3 (33.3%).

time to viral-, 16.7% lower, relative time 0.83, treatment 27, control 3.

Pott-Junior et al., 3/9/2021, Randomized Controlled Trial, Brazil, South America, peer-reviewed, 10 authors, dosage 200μg/kg single dose, dose varies in three arms 100, 200, 400μg/kg.

Chamie-Quintero et al., OSF Preprints (Preprint)

Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, p=.002 for effect by state, then 13-fold increase after ivermectin use restricted

Analysis of ivermectin use in Peru concluding that ivermectin most likely caused 14 times reductions in excess deaths in Peru, prior to 13 times increase after reversal of ivermectin use. Authors conclude that the results strongly suggest that ivermectin can complement vaccination. They note that the potential mechanism of action, competitive binding with the SARS-CoV-2 spike protein, is likely to be non-epitope specific, possibly maintaining efficacy against emerging mutant strains.

Chamie-Quintero et al., 3/8/2021, preprint, 3 authors.

Guzman et al., medRxiv, doi:10.1101/2021.03.04.21252084 (Preprint)

Factors associated with increased mortality in critically ill COVID-19 patients in a Mexican public hospital: the other faces of health system oversaturation

Retrospective 196 critically ill patients in Mexico. Patients overlap with the existing RCT by Beltran-Gonzalez (NCT04391127). This preprint shows a larger treated population and greater (non-statistically significant) improvement with ivermectin, RR 0.81 [0.53-1.24].

Guzman et al., 3/8/2021, retrospective, Mexico, North America, preprint, 11 authors.

Galan et al., Pathogens and Global Health, doi:10.1080/20477724.2021.1890887 (Peer Reviewed)

Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection

RCT 168 very late stage severe condition hospitalized patients comparing CQ, HCQ, and ivermectin not showing significant differences. Authors were unable to add a control arm due to ethical issues.

Authors claim that "the mortality rates of the three groups are very similar to historical reports of other studies that used placebo in hospitalized patients", without providing any reference. However [1] shows 43% hospital mortality in the northern region of Brazil, where the study was performed, from which we can estimate the mortality with ivermectin in this study is 47% lower, RR 0.53. Further, the study is restricted to more severe cases, hence the expected mortality may be higher.

[1] sciencedirect.com/science/article/pii/S2214109X20302850

Galan et al., 3/8/2021, peer-reviewed, 19 authors.

Descotes, J., ImmunoSafe Consultance (Preprint)

Medical Safety of Ivermectin

Safety analysis of >350 articles showing that ivermectin has an excellent safety profile. The author notes that "no severe adverse event has been reported in dozens of completed or ongoing studies involving thousands of participants worldwide to evaluate the efficacy of ivermectin against COVID-19".

Descotes et al., 3/5/2021, preprint.

López-Medina et al., JAMA, doi:10.1001/jama.2021.3071 (Peer Reviewed)

Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial

An open letter, signed by >100 physicians, concluding this study is fatally flawed can be found at [1].

Phone survey based RCT with low risk patients, 200 ivermectin and 198 control, showing lower mortality, lower disease progression, lower treatment escalation, and faster resolution of symptoms with treatment, without reaching statistical significance. Authors find the results of this trial alone do not support the use of ivermectin. However the effects are all positive, especially for serious outcomes which are unable to reach statistical significance with the very small number of events in the low risk population.

With the low risk patient population, there is little room for improvement with an effective treatment - 59/57% (IVM/control) recovered within the first 2 days to either "no symptoms" or "not hospitalized and no limitation of activities"; 73/69% within 5 days. Less than 3% of all patients ever deteriorated.

The primary outcome was changed mid-trial, it was originally clinical deterioration, which is more meaningful, and shows greater benefit. The new outcome of resolution of symptoms includes "not hospitalized and no limitation of activities" as a negative outcome and is not very meaningful in terms of assessing how much treatment reduces serious outcomes. Using this measure could completely invalidate results - for example a treatment that eliminates all COVID-19 symptoms but has a temporary minor adverse event could be seen as worse.

Authors state that "preliminary reports of other randomized trials of ivermectin as treatment for COVID-19 with positive results have not yet been published in peer-reviewed journals", however there were actually 8 peer-reviewed RCTs with positive effects published prior to this paper (and 19 total peer-reviewed studies with positive effects).

Authors advised taking ivermectin on an empty stomach, reducing lung tissue concentration by ~2.5x [2].

76 patients were excluded due to control patients receiving ivermectin. However, there was a similar percentage of adverse events like diarrhea, nausea, and abdominal pain in both treatment and control groups. These are potential non-serious side effects of treatment and suggest that it is possible that many more control patients received some kind of treatment.

Ivermectin was widely used in the population and available OTC at the time of the study. The study protocol only excluded patients with previous ivermectin use within 5 days, however other trials often monitor effects 10+ days after the last dose [3].

This study reportedly has an ethical issue whereby participants were told the study drug was "D11AX22" [4]. The editor-in-chief of JAMA initially offered to help with this issue, but later indicated that "JAMA does not review consent forms", however the lead author reportedly confirmed the issue. Therefore this paper may be retracted (JAMA has not indicated their response yet) [5, 6, 7].

The study protocol specifically allows "the use of other treatments outside of clinical trials". The paper provides no information on what other treatments were used, but other treatments were commonly used at the time, for example [8]. Additionally, the control group did about 5x better than anticipated for deterioration, also suggesting that the control patients used some kind of treatment. Patients which enroll in such a study may be more likely to learn about and use other treatments, especially since they do not know if they are receiving the study medication.

Most data was collected via surveys, without physical examination.

The trial protocol lists “the duration of supplemental oxygen” as an outcome but the results for this outcome are missing.

The study protocol was amended 4 times. Amendments 2-4 are provided but amendment 1 is missing. Amendment 2 increased the inclusion criteria to within 7 days of onset, including more later stage patients and reducing the expected effectiveness.

Grants and/or personal fees, including in some cases during the conduct of the study, were provided by Sanofi Pasteur, GlaxoSmithKline, Janssen, Merck, and Gilead.

Other issues can be found in the comments of the article [9].

For other confounding issues see: [10].

87% medication adherence. NCT04405843.

[1] jamaletter.com/

[2] twitter.com/Covid19Crusher/status/1367854845340844039

[3] osf.io/6m3ch/

[4] trialsitenews.com/jama-ivermectin-study-deceived-participants-on-study-drug/

[5] trialsitenews.com/jama-unable-to-confirm-ivermectin-study-consent-form-used-ivermectin/

[6] trialsitenews.com/jama-ivermectin-study-deception-of-study-participants-is-publicly-confirmed/

[7] francesoir.fr/societe-sante/la-tromperie-de-letude-jama-sur-livermectine-des-participants-letude-e..

[8] hsj.gr/medicine/is-there-a-correlation-between-changesin-hydroxychloroquine-use-and-mortalityrates..

[9] jamanetwork.com/journals/jama/fullarticle/2777389

[10] osf.io/bvznd

risk of death, 66.8% lower, RR 0.33, p = 0.50, treatment 0 of 200 (0.0%), control 1 of 198 (0.5%), continuity correction due to zero event.

risk of escalation of care, 60.8% lower, RR 0.39, p = 0.10, treatment 4 of 200 (2.0%), control 10 of 198 (5.1%), OR converted to RR.

risk of escalation of care with post-hoc <12h exclusion, 34.3% lower, RR 0.66, p = 0.51, treatment 4 of 200 (2.0%), control 6 of 198 (3.0%), OR converted to RR.

risk of deterioration by >= 2 points on an 8-point scale, 43.1% lower, RR 0.57, p = 0.35, treatment 4 of 200 (2.0%), control 7 of 198 (3.5%), OR converted to RR.

risk of fever post randomization, 24.8% lower, RR 0.75, p = 0.33, treatment 16 of 200 (8.0%), control 21 of 198 (10.6%), OR converted to RR.

risk of unresolved symptoms at day 21, 15.3% lower, RR 0.85, p = 0.53, treatment 36 of 200 (18.0%), control 42 of 198 (21.2%), OR converted to RR, Cox proportional-hazard model.

hazard ratio for lack of resolution of symptoms, 6.5% lower, RR 0.93, p = 0.53, treatment 200, control 198.

relative median time to resolution of symptoms, 16.7% lower, relative time 0.83, treatment 200, control 198.

López-Medina et al., 3/4/2021, Double Blind Randomized Controlled Trial, Columbia, South America, peer-reviewed, median age 37.0, 19 authors, dosage 300μg/kg days 1-5.

Saha et al., Structural Chemistry, doi:10.1007/s11224-021-01776-0 (preprint 3/1) (Peer Reviewed)

The Binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2

In SIlico analysis predicting that ivermectin has a large binding affinity for the SARS-CoV-2 spike protein. Three different computer modeling techniques show that ivermectin can inhibit SARS-CoV-2 entrance via hACE2.

Saha et al., 3/1/2021, peer-reviewed, 2 authors.

Beltran-Gonzalez et al., medRxiv, doi:10.1101/2021.02.18.21252037 (Peer Reviewed)

Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial

RCT late stage severe condition (93% SOFA ≥ 2, 96% APACHE ≥ 8) high comorbidity hospitalized patients in Mexico with 36 low dose ivermectin and 37 control patients not finding significant differences. NCT04391127.

risk of death, 14.4% lower, RR 0.86, p = 1.00, treatment 5 of 36 (13.9%), control 6 of 37 (16.2%).

risk of respiratory deterioration or death, 8.6% lower, RR 0.91, p = 1.00, treatment 8 of 36 (22.2%), control 9 of 37 (24.3%).

risk of no hospital discharge, 37.0% higher, RR 1.37, p = 0.71, treatment 4 of 36 (11.1%), control 3 of 37 (8.1%).

Beltran-Gonzalez et al., 2/23/2021, Double Blind Randomized Controlled Trial, Mexico, North America, peer-reviewed, mean age 53.8, 13 authors, dosage 12mg single dose, 18mg for patients >80kg.

BIRD Meeting 20th February 2021 (News)

BIRD Meeting 20th February 2021

The British Ivermectin Recommendation Development (BIRD) panel, with dozens of multi-national scientists & doctors, issued sweeping recommendations for the immediate global use of ivermectin.

BIRD et al., 2/20/2021, preprint, 1 author.

Elalfy et al., J. Med. Virol., doi:10.1002/jmv.26880 (Peer Reviewed)

Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-1

Non-randomized controlled trial with 62 mild and early moderate patients with home treatment with ivermectin + nitazoxanide + ribavirin + zinc, showing significantly faster viral clearance.

risk of no virological cure, 86.9% lower, RR 0.13, p < 0.001, treatment 7 of 62 (11.3%), control 44 of 51 (86.3%), day 15.

risk of no virological cure, 58.1% lower, RR 0.42, p < 0.001, treatment 26 of 62 (41.9%), control 51 of 51 (100.0%), day 7.

Elalfy et al., 2/16/2021, retrospective, Egypt, Middle East, peer-reviewed, 15 authors, dosage 18mg days 1, 4, 7, 10, 13, <90kg 18mg, 90-120kg 24mg, >120kg 30mg, this trial uses multiple treatments in the treatment arm (combined with nitazoxanide, ribavirin, and zinc) - results of individual treatments may vary.

Behera et al., Research Square, doi:10.21203/rs.3.rs-208785/v1 (Preprint)

Prophylactic role of ivermectin in SARS-CoV-2 infection among healthcare workers

Prospective prophylaxis study with 3,532 healthcare workers, 2,199 receiving two-dose ivermectin prophylaxis, showing adjusted relative risk of confirmed COVID-19 with treatment 0.17 [0.12-0.23] p<0.001.

186 patients took only the first dose, and no significant difference was observed for this group. The same group published an earlier small study with 115 ivermectin patients.

risk of COVID-19 case, 83.0% lower, RR 0.17, p < 0.001, treatment 45 of 2199 (2.0%), control 133 of 1147 (11.6%), two doses.

risk of COVID-19 case, 4.0% higher, RR 1.04, p = 0.85, treatment 23 of 186 (12.4%), control 133 of 1147 (11.6%), patients only receiving the first dose.

Behera et al., 2/15/2021, prospective, India, South Asia, preprint, 13 authors, dosage 300μg/kg days 1, 4.

Schwartz, E., International Ivermectin for Covid Conference, April 24-25, 2021 (Preprint)

Ivermectin vs. placebo treatment in non-hospitalized patients with COVID-19 - a double blind, randomized controlled trial

Double blind RCT for mild-moderate COVID-19 outpatients in Israel showing significantly faster reduction in viral load with treatment, and lower hospitalization with treatment. The one treatment hospitalization was a few hours after treatment and the patient improved and was discharged quickly. There were no safety issues. Sheba IRB-7156/20. NCT04429711.

risk of hospitalization, 70.2% lower, RR 0.30, p = 0.34, treatment 1 of 47 (2.1%), control 3 of 42 (7.1%).

risk of no virological cure, 42.2% lower, RR 0.58, p = 0.01, treatment 16 of 49 (32.7%), control 25 of 45 (55.6%), adjusted, OR converted to RR, multivariable logistic regression, day 6, Ct>30.

risk of no virological cure, 70.2% lower, RR 0.30, p = 0.02, treatment 4 of 47 (8.5%), control 12 of 42 (28.6%), day 6, non-infectious samples (Ct>30 or non-viable culture).

risk of no virological cure, 51.9% lower, RR 0.48, p = 0.08, treatment 7 of 47 (14.9%), control 13 of 42 (31.0%), day 10, Ct>30.

risk of no virological cure, 57.9% lower, RR 0.42, p = 0.02, treatment 8 of 47 (17.0%), control 17 of 42 (40.5%), day 8, Ct>30.

risk of no virological cure, 44.7% lower, RR 0.55, p = 0.05, treatment 13 of 47 (27.7%), control 21 of 42 (50.0%), day 6, Ct>30.

risk of no virological cure, 31.9% lower, RR 0.68, p = 0.16, treatment 13 of 28 (46.4%), control 15 of 22 (68.2%), day 4, Ct>30.

Schwartz et al., 2/12/2021, Double Blind Randomized Controlled Trial, Israel, Middle East, preprint, 1 author, dosage 12mg days 1-3, 15mg for patients >= 70kg.

Lima-Morales (Peer Reviewed)

Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico

Prospective trial of 768 COVID-19 outpatients in Mexico, 481 treated with ivermectin, AZ, montelukast, and aspirin, and 287 control patients with various treatments, showing significantly lower mortality and hospitalization, and significantly higher recovery at 14 days with treatment.

risk of death, 77.7% lower, RR 0.22, p < 0.001, treatment 15 of 481 (3.1%), control 52 of 287 (18.1%), adjusted, OR converted to RR, multivariate.

risk of hospitalization, 67.4% lower, RR 0.33, p < 0.001, treatment 44 of 481 (9.1%), control 89 of 287 (31.0%), adjusted, OR converted to RR, multivariate.

risk of no recovery, 58.6% lower, RR 0.41, p < 0.001, treatment 75 of 481 (15.6%), control 118 of 287 (41.1%), adjusted, OR converted to RR, recovery at day 14 after symptoms, multivariate.

Lima-Morales et al., 2/10/2021, prospective, Mexico, North America, peer-reviewed, 9 authors, dosage 12mg single dose, this trial uses multiple treatments in the treatment arm (combined with azithromycin, montelukast, and aspirin) - results of individual treatments may vary.

Mohan et al., Research Square, doi:10.21203/rs.3.rs-191648/v1 (Preprint)

Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial

RCT in India with low risk patients, comparing 24mg ivermectin, 12mg ivermectin, and placebo showing non-statistically significant improvements in recovery and PCR+ status (day 5 both arms, day 7 24mg only) with treatment, and showing greater improvement for the higher dose arm. Viral load decline was similar in all arms. There were no deaths or use of mechanical ventilation. There were no safety concerns. We note that our pre-specified protocol prioritizes clinical outcome results over PCR results.

risk of no discharge at day 14, 62.5% lower, RR 0.38, p = 0.27, treatment 2 of 40 (5.0%), control 6 of 45 (13.3%), ivermectin 24mg.

risk of no discharge at day 14, 43.8% lower, RR 0.56, p = 0.49, treatment 3 of 40 (7.5%), control 6 of 45 (13.3%), ivermectin 12mg.

risk of no virological cure, 10.3% lower, RR 0.90, p = 0.65, treatment 20 of 36 (55.6%), control 26 of 42 (61.9%), ivermectin 24mg, day 7.

risk of no virological cure, 3.2% higher, RR 1.03, p = 1.00, treatment 23 of 36 (63.9%), control 26 of 42 (61.9%), ivermectin 12mg, day 7.

risk of no virological cure, 23.8% lower, RR 0.76, p = 0.18, treatment 21 of 40 (52.5%), control 31 of 45 (68.9%), ivermectin 24mg, day 5.

risk of no virological cure, 5.6% lower, RR 0.94, p = 0.82, treatment 26 of 40 (65.0%), control 31 of 45 (68.9%), ivermectin 12mg, day 5.

Mohan et al., 2/2/2021, Double Blind Randomized Controlled Trial, India, South Asia, preprint, 27 authors, dosage 400μg/kg single dose, 200μg/kg also tested.

Castaneda-Sabogal et al., medRxiv, doi:10.1101/2021.01.26.21250420 (Preprint) (meta analysis)

Outcomes of Ivermectin in the treatment of COVID-19: a systematic review and meta-analysis

Student-written meta analysis of a very small subset of studies exhibiting very high bias and significant flaws. Some of the problems:

- As of the publication date, there are 35 studies, authors include only 4. (They list 5, but two are the same study, preprint and published version).

- From the 17 RCTs, authors include 0.

- Authors include only late treatment studies, excluding all 10 early treatment studies and all 10 prophylaxis studies.

- Authors did not locate 13 studies, despite this being trivial from existing meta analyses.

- There is no logic in the exclusion reasons. For example, they include the most biased study to date, Soto-Becerra, and assign the highest weight to it.

- Authors randomly exclude letters but include preprints (excluding letters to help avoid positive results, including preprints to include Soto-Becerra).

- Soto-Becerra has clear evidence of extreme bias. The study presents 30 day results and extended KM curves up to day 43 for ivermectin. At 30 days the result is negative but reverts (as do all treatments in the study) and becomes positive before day 43. Authors of this meta analysis ignore the extended followup. Soto-Becerra is a database analysis that includes anyone with ICD-10 COVID-19 codes which includes asymptomatic PCR+ patients, therefore many patients in the control group are likely asymptomatic with regards to SARS-CoV-2, but in the hospital for another reason. For those that had symptomatic COVID-19, there is also likely significant confounding by indication. In this study all medications show higher mortality at day 30, which is consistent with asymptomatic (for COVID-19) or mild condition patients being more common in the control group. For ivermectin they show 30 day mortality aHR = 1.39 [0.88 - 2.22]. KM curves show that the treatment groups were in more serious condition, and also that after about day 35 survival became better with ivermectin. More than the total excess mortality happened on the first day. This is consistent with treated patients being in more serious condition, and with many of the control group patients being in hospital for something unrelated to COVID-19. Authors use a machine learning based propensity scoring system that appears over-parameterized and likely to result in significant overfitting and inaccurate results. Essentially they test for all interactions between two and three covariates. The nature and large number of covariates means many random correlations may be found. COVID-19 severity is not used. In summary, this is the lowest quality ivermectin study to date. This study also does not compare treatments with a control group not receiving the treatment - authors put patients receiving treatments after 48 hours in the control group. Authors also state that outcomes within 24 hours were excluded, however KM curves show significant mortality at day 1 (only for the treatment groups).

- We checked the reported results for the mortality outcome and found they do not appear to match the actual papers.

- Rajter: authors list mortality as 13/85 (treatment), 24/74 (control), the paper shows (for the matched cohort) 13/98 (treatment), 24/98 (control). The adjusted result in the paper is OR 0.27 [0.09-0.80] (multivariate) or OR 0.47 [0.22-0.99] (PSM). These correspond to RR 0.33 and 0.54 respectively, or logRR -1.1 and -0.62. However authors here show logRR 0.54 and 0.85 - they include the study twice (preprint and published). The preprint and published papers have the same multivariate result, the PSM result was added in the published paper. Neither of the two results the authors use match the actual results.

- Khan: the paper shows RR 0.13, logRR -2.0. Authors show logRR 0.13.

- Soto-Becerra at day 30 shows wHR 1.39 [0.88-2.22], and day 43 weighted KM 0.82 [0.76-0.88]. These correspond to logRR 0.33 and -0.19. Authors show logRR 1.75.

- Gorial: there is zero mortality with treatment in this paper. Using the typical continuity correction, the paper shows RR 0.29 when accounting for the different group sizes, or 0.86 when using naive continuity correction that does not account for the very different group sizes. These correspond to logRR -1.24 or -0.15. Authors show logRR 0.60.

- Authors did not locate and reference the existing widely known meta-analyses from well-known researchers - Kory et al., Hill et al., Lawrie et al.

For more issues see: [1, 2]

Authors on Twitter: [3, 4, 5, 6]

[1] twitter.com/Covid19Crusher/status/1354463260599328778

[2] twitter.com/joshuanbarbozam/status/1354471295690403840

[3] twitter.com/DiegoMichilot

[4] twitter.com/carlostoro_29

[5] twitter.com/christiansr96

[6] twitter.com/joshuanbarbozam

Castaneda-Sabogal et al., 1/27/2021, preprint.

Eweas et al., Frontiers in Microbiology, doi:10.3389/fmicb.2020.592908 (Peer Reviewed)

Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2

Molecular docking analysis showing that ivermectin efficiently binds to the viral S protein as well as the human cell surface receptors ACE-2 and TMPRSS2; therefore, it might be involved in inhibiting the entry of the virus into the host cell. It also binds to Mpro and PLpro of SARS-CoV-2; therefore, it might play a role in preventing the post-translational processing of viral polyproteins. The highly efficient binding of ivermectin to the viral N phosphoprotein and nsp14 is suggestive of its role in inhibiting viral replication and assembly.

Eweas et al., 1/25/2021, peer-reviewed, 3 authors.

Errecalde et al., Journal of Pharmaceutical Sciences, doi:10.1016/j.xphs.2021.01.017 (Peer Reviewed)

Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model

Animal study of a novel spray formulation of ivermectin, showing an advantage of the spray formulation in terms of fast attainment of high and
persistent ivermectin concentrations in nasopharyngeal tissue.

Errecalde et al., 1/23/2021, peer-reviewed, 15 authors.

Chamie-Quintero et al., Preprint, doi:10.2139/ssrn.3765018 (Preprint)

Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments

Analysis of ivermectin usage within states in Peru showing sharp reductions in COVID-19 deaths corresponding to the usage of ivermectin treatment.

Chamie-Quintero et al., 1/21/2021, preprint, 3 authors.

Mody et al., Communications Biology, doi:10.1038/s42003-020-01577-x (Peer Reviewed) (In Vitro)

Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents

Computational molecular modeling screening and in vitro analysis for inhibitory effects on SARS-CoV-2 specific 3CLpro enzyme, showing that ivermectin blocked more than 85% of 3CLpro activity of SARS-CoV-2. Antiviral activity of ivermectin mediated through the blocking of α/β1 importin has been previously established, this analysis suggests an additional antiviral mechanism of ivermectin for SARS-CoV-2 via inhibitory effects on 3CLpro.

Mody et al., 1/20/2021, peer-reviewed, 9 authors.

Rezai et al., IRCT20111224008507N3 (Preprint)

Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in 2020

RCT in Iran showing shorter time to clinical recovery with Ivermectin.

Results are from: [1]
Trial details: [2] (double blind according to the trial registration)

[1] c19ivermectin.com/hill.html

[2] en.irct.ir/trial/49174

recovery time, 21.2% lower, relative time 0.79, p = 0.02, treatment 51, control 52.

hospitalization time, 17.9% lower, relative time 0.82, p = 0.01, treatment 51, control 52.

Rezai et al., 1/19/2021, Double Blind Randomized Controlled Trial, Iran, Middle East, preprint, 1 author, dosage 200μg/kg single dose.

Hill et al., Research Square, doi:10.21203/rs.3.rs-148845/v1 (Preprint) (meta analysis)

Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection

Meta analysis of 18 ivermectin RCTs with 2,282 patients showing faster viral clearance (dose and duration dependent), improved clinical recovery, and lower hospitalization and mortality. In six RCTs of moderate or severe infection, there was a 75% reduction in mortality, RR 0.25 [0.12-0.52], p = 0.0002.

A sponsor reportedly required the conclusion of this paper to be changed against the wishes of the authors (to suggest that more trials should be done as opposed to the existing evidence being sufficient) [1, 2, 3].

[1] francesoir.fr/videos-les-debriefings/le-scandale-de-livermectine-tess-lawrie-le-retour

[2] youtube.com/watch?v=y2FWPQm6sxw&t=3s

[3] reddit.com/r/ivermectin/comments/m5kr7b/dr_tess_lawrie_discusses_her_ivermectin/

risk of death, 75.0% lower, RR 0.25, p < 0.001.

Hill et al., 1/19/2021, preprint, 40 authors.

Raad et al., ChiCTR2000033627 (Preprint)

In vivo use of ivermectin (IVR) for treatment for corona virus infected patients (COVID-19): a randomized controlled trial

RCT in Lebanon showing significantly lower viral load at day 3, and lower hospitalization.

Results are from: [1]

[1] c19ivermectin.com/hill.html

risk of hospitalization, 85.7% lower, RR 0.14, p = 0.24, treatment 0 of 50 (0.0%), control 3 of 50 (6.0%), continuity correction due to zero event.

risk of viral load, 59.0% lower, RR 0.41, p = 0.01, treatment 50, control 50, percentage relative improvement in Ct value with treatment at day 3.

Raad et al., 1/16/2021, Single Blind Randomized Controlled Trial, Lebanon, Middle East, preprint, 1 author, dosage 200μg/kg single dose.

Bukhari et al., medRxiv, doi:10.1101/2021.02.02.21250840 (results 1/16) (Preprint)

Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease

RCT of relatively low risk hospitalized patients with 50 ivermectin and 50 control patients showing significantly faster viral clearance with treatment. 9 patients in the treatment arm were lost to followup compared with 5 in the control arm, which could be in part due to faster recovery with treatment. There were no safety concerns. No mortality was reported. The numbers in Table 3 are the number of patients that became negative on that day, i.e., non-cumulative. NCT04392713.

risk of no virological cure, 82.4% lower, RR 0.18, p < 0.001, treatment 4 of 41 (9.8%), control 25 of 45 (55.6%), day 7.

risk of no virological cure, 38.7% lower, RR 0.61, p < 0.001, treatment 24 of 41 (58.5%), control 43 of 45 (95.6%), day 3.

Bukhari et al., 1/16/2021, Randomized Controlled Trial, Pakistan, Middle East, preprint, 10 authors, dosage 12mg single dose.

Kory et al., Frontiers in Pharmacology, doi:10.3389/fphar.2021.643369 (Review) (Peer Reviewed)

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has been widely used, showing efficacy of ivermectin in prophylaxis and treatment of COVID-19. This paper was censored by the journal after acceptance [1].

[1] the-scientist.com/news-opinion/frontiers-removes-controversial-ivermectin-paper-pre-publication-68..

Kory et al., 1/13/2021, peer-reviewed, 10 authors.

Okumuş et al., NCT04646109 (Preprint)

Evaluation of the Effectiveness and Safety of Adding Ivermectin to Treatment in Severe COVID-19 Patients

Small RCT for severe COVID-19 comparing the addition of ivermectin to SOC (low dose HCQ+AZ+favipiravir), with 30 treatment and 30 control patients in Turkey, showing lower mortality and faster clinical recovery. Authors also investigate the presence of gene mutations that alter ivermectin metabolism, predicting that ivermectin can be used safely without serious side effects in patients without MDR-1/ABCB1 and/or CYP3A4 gene mutation, and recommending monitoring and appropriate treatment if necessary when sequencing is unavailable.

risk of death, 33.3% lower, RR 0.67, p = 0.55, treatment 6 of 30 (20.0%), control 9 of 30 (30.0%).

risk of no improvement at day 10, 42.9% lower, RR 0.57, p = 0.18, treatment 8 of 30 (26.7%), control 14 of 30 (46.7%).

risk of no improvement at day 5, 15.8% lower, RR 0.84, p = 0.60, treatment 16 of 30 (53.3%), control 19 of 30 (63.3%).

risk of no virological cure, 80.0% lower, RR 0.20, p = 0.02, treatment 2 of 16 (12.5%), control 5 of 8 (62.5%), day 10.

Okumuş et al., 1/12/2021, Double Blind Randomized Controlled Trial, Turkey, Middle East, preprint, 15 authors, dosage 200μg/kg days 1-5, 36-50kg - 9mg, 51-65kg - 12mg, 66-79kg - 15mg, >80kg 200μg/kg.

Chahla et al., medRxiv, doi:10.1101/2021.03.26.21254398 (Preprint)

A randomized trial - intensive treatment based in ivermectin and iota-carrageenan as pre-exposure prophylaxis for COVID-19 in healthcare agents

Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina, 117 healthcare workers treated with ivermectin and iota-carrageenan, and 117 controls, showing significantly lower cases with treatment. There were no moderate/severe cases with treatment vs. 10 in the control group. There were 4 cases with treatment (all mild) vs. 25 for the control group. NCT04701710.

risk of COVID-19 case, 95.2% lower, RR 0.05, p = 0.002, treatment 0 of 117 (0.0%), control 10 of 117 (8.5%), continuity correction due to zero event, moderate/severe COVID-19.

risk of COVID-19 case, 84.0% lower, RR 0.16, p < 0.001, treatment 4 of 117 (3.4%), control 25 of 117 (21.4%), adjusted, OR converted to RR, all cases.

risk of COVID-19 case, 84.0% lower, RR 0.16, p < 0.001, treatment 4 of 117 (3.4%), control 25 of 117 (21.4%), all cases.

Chahla et al., 1/11/2021, Randomized Controlled Trial, Argentina, South America, preprint, 1 author, dosage 12mg weekly, this trial uses multiple treatments in the treatment arm (combined with iota-carrageenan) - results of individual treatments may vary.

Bousquet-Melou et al., Preprint, doi:10.22541/au.161047848.80388481/v1 (Preprint)

Large Impact of obesity on the disposition of ivermectin, moxidectin and eprinomectin in a canine model: relevance for COVID-19 patients

Animal dosing study with an obese dog model concluding that ivermectin maintenance doses should be based on lean body weight and not the total body weight in obese subjects, while the loading dose should be based on the total body weight.

Bousquet-Melou et al., 1/11/2021, preprint, 5 authors.

Formiga et al., J. Control Release, doi:10.1016/j.jconrel.2020.10.009 (Review) (Peer Reviewed)

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Review hypothesizing that micro- and nanotechnology-based formulations of ivermectin for the pulmonary delivery of ivermectin may be beneficial for use with COVID-19.

Formiga et al., 1/10/2021, peer-reviewed, 6 authors.

Kirti et al., medRxiv, doi:10.1101/2021.01.05.21249310 (Preprint)

Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial

RCT with 112 mild and moderate COVID-19 patients in India, showing lower mortality, ventilation, and ICU admission, although not statistically significant due to the small number of events. There was no mortality in the treatment arm (55 patients) versus 7% (4 of 57) in the control arm. The PCR result is subject to confounding by biased loss of followup, with 23 lost in the treatment group and 13 in the control group, and 8 more people in the treatment group discharged before day 6.

risk of death, 88.7% lower, RR 0.11, p = 0.12, treatment 0 of 55 (0.0%), control 4 of 57 (7.0%), continuity correction due to zero event.

risk of mechanical ventilation, 79.3% lower, RR 0.21, p = 0.09, treatment 1 of 55 (1.8%), control 5 of 57 (8.8%).

risk of ICU admission, 13.6% lower, RR 0.86, p = 0.80, treatment 5 of 55 (9.1%), control 6 of 57 (10.5%).

risk of no virological cure, 11.6% higher, RR 1.12, p = 0.35, treatment 42 of 55 (76.4%), control 39 of 57 (68.4%).

Kirti et al., 1/9/2021, Double Blind Randomized Controlled Trial, India, South Asia, preprint, 11 authors, dosage 12mg days 1, 2.

Chamie, J. (News)

COVID-19 in Mexico

Comparison of COVID-19 death rates in Mexico showing that the only state using ivermectin has a dramatically lower rate.

Chamie et al., 1/8/2021, preprint, 1 author.

Babalola et al., QJM: An International Journal of Medicine, doi:10.1093/qjmed/hcab035 (preprint 1/6) (Peer Reviewed)

Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos

Small RCT comparing ivermectin 6mg & 12mg q84hr with lopinavir/ritonavir, showing a statistically significant and dose dependent effect of ivermectin on reducing the time to PCR-.

adjusted risk of viral+ at day 5, 63.9% lower, RR 0.36, p = 0.11, treatment 40, control 20, adjusted.

risk of no virological cure, 58.0% lower, RR 0.42, p = 0.01, treatment 20, control 20, 12mg - Cox proportional hazard model.

risk of no virological cure, 40.5% lower, RR 0.60, p = 0.12, treatment 20, control 20, 6mg - Cox proportional hazard model.

time to viral-, 49.2% lower, relative time 0.51, treatment 20, control 20, 12mg.

time to viral-, 34.4% lower, relative time 0.66, treatment 20, control 20, 6mg.

Babalola et al., 1/6/2021, Double Blind Randomized Controlled Trial, Nigeria, Africa, peer-reviewed, baseline oxygen requirements 8.3%, 10 authors, dosage 12mg or 6mg q84h for two weeks, this trial compares with another treatment - results may be better when compared to placebo.

Hirsch et al., Microbiology & Infectious Diseases (Peer Reviewed)

Ivermectin as Prophylaxis Against COVID-19 Retrospective Cases Evaluation

Report on ivermectin prophylaxis for healthcare workers in a hospital in Argentina, showing 0 cases in the 162 participants. Dosage was 0.2mg/kg weekly for eight weeks, followed by 4 months rest.

Hirsch et al., 1/6/2021, peer-reviewed, 2 authors.

Lawrie et al., Preprint (Preprint) (meta analysis)

Ivermectin reduces the risk of death from COVID-19 – a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance

Meta analysis confirming the effectiveness of ivermectin for COVID-19, showing ivermectin treatment mortality relative risk RR 0.17 [0.18-0.35] and prophylaxis cases RR 0.12 [0.08-0.18].

risk of death, 83.0% lower, RR 0.17, p < 0.001, treatment 8 of 585 (1.4%), control 44 of 522 (8.4%).

Lawrie et al., 1/3/2021, preprint, 1 author.

Wijaya et al., Cermin Dunia Kedokteran, 47:7 (Peer Reviewed)

Ivermectin as a Potential Therapeutic Agent for COVID-19 – case studies

Case report on 3 confirmed cases of COVID-19 with significant clinical and radiological improvement after a single dose of ivermectin.

Wijaya et al., 12/31/2020, peer-reviewed, 2 authors.

Madrid et al., Heliyon, doi:10.1016/j.heliyon.2020.e05820 (Peer Reviewed)

Safety of oral administration of high doses of ivermectin by means of biocompatible polyelectrolytes formulation

In vivo analysis of the safety of high dose ivermectin with a Corydoras fish animal model.

Madrid et al., 12/31/2020, peer-reviewed, 8 authors.

McCullough et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.264 (Review) (Peer Reviewed)

Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)

Review urging early treatment of COVID-19 with sequential multidrug treatment that has been shown to be safe and effective. Proposed treatment includes zinc, vitamin D & C, quercetin, and depending on age, comorbidities, and symptoms may include >=2 of HCQ, ivermectin, favipiravir; AZM/DOXY; corticosteroids; colchicine; bamlanivimab; aspirin; LMWH; and supplemental oxygen.

McCullough et al., 12/30/2020, peer-reviewed, 58 authors.

Procter et al., Reviews in Cardiovascular Medicine, doi:10.31083/j.rcm.2020.04.260 (Peer Reviewed)

Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection

Retrospective 922 outpatients, with 320 treated early due to age>50 or comorbidities, showing 2.2% hospitalization and 0.3% death, which authors note is considerably lower than reported in other studies in their region.

At least two of zinc, HCQ, and ivermectin were used, along with one antibiotic, and budesonide and/or dexamethasone.

Procter et al., 12/30/2020, peer-reviewed, 6 authors.

Hill, A., Preprint (Preprint) (meta analysis)

Meta-analysis of clinical trials of ivermectin to treat COVID-19 infection

WHO-funded meta analysis showing ivermectin treatment mortality relative risk RR 0.17 [0.08-0.35] for RCTs and RR 0.28 [0.13-0.62] for RCTs and observational studies, and confirming a dose-response effect.

Hill et al., 12/27/2020, preprint, 1 author.

Jeffreys et al., bioRxiv, doi:10.1101/2020.12.23.424232 (Preprint) (In Vitro)

Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2

In Vitro study showing enhanced antiviral activity of ivermectin and remdesivir in combination.

Jeffreys et al., 12/24/2020, preprint, 15 authors.

Vallejos et al., Trials, doi:10.1186/s13063-020-04813-1 (Preprint)

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial

Report on ivermectin prophylaxis in a hospital in Argentina showing lower cases for healthcare workers taking ivermectin. Preliminary results from: [1].

[1] twitter.com/Covid19Crusher/status/1365420061859717124

risk of COVID-19 case, 73.4% lower, RR 0.27, p < 0.001, treatment 13 of 389 (3.3%), control 61 of 486 (12.6%).

Vallejos et al., 12/20/2020, retrospective, Argentina, South America, preprint, 1 author, dosage 12mg weekly.

Kory et al., FLCCC Alliance (Preprint) (meta analysis)

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Meta analysis of ivermectin clinical studies and natural experiments where ivermectin has been widely used, showing efficacy of ivermectin in prophylaxis and treatment of COVID-19.

risk of death, 69.0% lower, RR 0.31, p < 0.001, treatment 35 of 1551 (2.3%), control 191 of 1957 (9.8%), OR converted to RR.

Kory et al., 12/18/2020, preprint, 10 authors.

Alam et al., European Journal ofMedical and Health Sciences, doi:10.24018/ejmed.2020.2.6.599 (Peer Reviewed)

Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study

91% reduction in COVID-19 cases with ivermectin prophylaxis. 118 healthcare workers in Bangladesh, 58 receiving ivermectin 12mg monthly, showing RR 0.094, p < 0.0001.

risk of COVID-19 case, 90.6% lower, RR 0.09, p < 0.001, treatment 4 of 58 (6.9%), control 44 of 60 (73.3%).

Alam et al., 12/15/2020, prospective, Bangladesh, South Asia, peer-reviewed, 13 authors, dosage 12mg monthly.

Afsar et al., SSRN (Preprint)

Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting

Small 95 patient study in Pakistan adding ivermectin to standard of care (HCQ+AZ) for outpatients with mild/moderate suspected COVID-19, showing faster resolution of fever with ivermectin.

The low dose HCQ used in this study may not reach therapeutic levels fast enough to make a significant impact.

risk of fever at day 14, 92.2% lower, RR 0.08, p = 0.04, treatment 0 of 37 (0.0%), control 7 of 53 (13.2%), continuity correction due to zero event.

Afsar et al., 12/15/2020, retrospective, Pakistan, South Asia, preprint, 6 authors, dosage 12mg days 1-6.

Hussain et al., International Journal of Molecular and Immuno Oncology, doi:10.25259/IJMIO_30_2020 (Peer Reviewed)

Outcome of ivermectin and doxycycline in cancer patients with COVID-19: A positive experience in Bangladesh

Small case study of ivermectin + doxycycline with 8 cancer patients, with all patients becoming PCR- by day 6 when tested again.

Hussain et al., 12/11/2020, peer-reviewed, 3 authors.

Chaccour et al., EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720 (preprint 12/7) (Peer Reviewed)

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

Tiny RCT for early treatment of mild COVID-19 in low risk patients, with 12 400mcg/kg single dose ivermectin patients and 12 control patients, showing significantly faster viral load reduction and symptom improvement with ivermectin.

Average median viral load for gene E and gene N mid-viral recovery at day 7:

Ivermectin: 1637
control: 30175

Probability of symptoms at day 28, adjusted for the time since onset and day of followup:

Ivermectin: = 0.26 [0.10-0.42]
control: 0.55 [0.33-0.77]

(details are in the supplementary appendix)

symptom probability, 52.9% lower, RR 0.47, p < 0.05, treatment 12, control 12, relative probability of symptoms at day 28, mixed effects logistic regression, data in supplementary appendix.

viral load, 94.6% lower, relative load 0.05, treatment 12, control 12, day 7 mid-recovery, data in supplementary appendix.

Chaccour et al., 12/7/2020, Double Blind Randomized Controlled Trial, Spain, Europe, peer-reviewed, 23 authors, dosage 400μg/kg single dose.

Kalfas et al., medRxiv, doi:10.1101/2020.11.30.20236570 (Preprint)

The therapeutic potential of ivermectin for COVID-19: a systematic review of mechanisms and evidence

Review of ivermectin mechanisms and 8 trials, showing positive mortality benefit, reduced time to clinical recovery, reduced incidence of disease progression, and decreased duration of hospital admission in patients across all stages of clinical severity.

Kalfas et al., 12/4/2020, preprint, 4 authors.

Surnar et al., ACS Pharmacol. Transl. Sci., doi:10.1021/acsptsci.0c00179 (Peer Reviewed) (In Vitro)

Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19

In Vitro analysis of ivermectin with orally administrable nanoparticles showing efficacy for decreasing expression of the viral spike protein and ACE2. Inhibition of nuclear transport activities mediated through proteins such as importin α/β1 heterodimer are also considered as a possible mechanism of action. The technology may work for other coronaviruses as well.

Surnar et al., 12/4/2020, peer-reviewed, 4 authors.

Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191 (Peer Reviewed)

A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness

Small 72 patient RCT of ivermectin and ivermectin + doxycycline showing faster recovery with ivermectin.

Ivermectin group: 12mg daily for 5 days
Ivermectin + doxycycline: 12mg ivermectin single dose, 200mg doxycycline + 100mg bid 4 days

risk of unresolved symptoms, 85.0% lower, RR 0.15, p = 0.09, treatment 0 of 17 (0.0%), control 3 of 19 (15.8%), continuity correction due to zero event, day 7 fever ivermectin.

risk of unresolved symptoms, 62.7% lower, RR 0.37, p = 0.35, treatment 1 of 17 (5.9%), control 3 of 19 (15.8%), day 7 fever ivermectin + doxycycline.

risk of no virological cure, 42.5% lower, RR 0.58, p = 0.01, treatment 11 of 22 (50.0%), control 20 of 23 (87.0%), day 7 ivermectin.

risk of no virological cure, 20.0% lower, RR 0.80, p = 0.28, treatment 16 of 23 (69.6%), control 20 of 23 (87.0%), day 7 ivermectin + doxycycline.

risk of no virological cure, 62.7% lower, RR 0.37, p = 0.02, treatment 5 of 22 (22.7%), control 14 of 23 (60.9%), day 14 ivermectin.

risk of no virological cure, 35.7% lower, RR 0.64, p = 0.24, treatment 9 of 23 (39.1%), control 14 of 23 (60.9%), day 14 ivermectin + doxycycline.

time to viral-, 23.6% lower, relative time 0.76, p = 0.02, treatment 22, control 23, ivermectin.

time to viral-, 9.4% lower, relative time 0.91, p = 0.27, treatment 23, control 23, ivermectin + doxycycline.

hospitalization time, 1.0% lower, relative time 0.99, ivermectin.

hospitalization time, 4.1% higher, relative time 1.04, ivermectin + doxycycline.

Ahmed et al., 12/2/2020, Double Blind Randomized Controlled Trial, Bangladesh, South Asia, peer-reviewed, mean age 42.0, 15 authors, dosage 12mg days 1-5, ivermectin + doxycycline group took only a single dose of ivermectin.

Chamie, J. (News)

The effect of using ivermectin to control COVID-19 in Chiapas

After starting to distribute ivermectin in drug kits in July, the Mexican state of Chiapas has seen a dramatic divergence from other states with much lower mortality [1, 2].

[1] twitter.com/Covid19Crusher/status/1334448128922165248

[2] sie7edechiapas.com/post/repartir%C3%A1n-10-mil-kits-con-ivermectina-para-combatir-covid-19-en-tuxtla

Chamie et al., 12/2/2020, preprint, 1 author.

Alonso et al., (Preprint)

COVID-19: Uso de ivermectina

Observational study in Argentina showing significantly lower mortality in the 60 days after adopting ivermectin compared to the 60 days before, relative risk RR 0.082, p=0.003.

risk of death, 91.8% lower, RR 0.08, p = 0.009, treatment 1 of 311 (0.3%), control 5 of 128 (3.9%).

Alonso et al., 12/1/2020, retrospective, Argentina, South America, preprint, 1 author, dosage not specified.

Bernigaud et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231 (Peer Reviewed)

Ivermectin benefit: from scabies to COVID-19, an example of serendipity

69 residents of a French care home, median age 90, were treated with ivermectin for a scabies outbreak. 3,062 residents in 45 nearby comparable homes were used as controls.

7 of 69 treated patients had probable or certain COVID-19, with no serious cases and no deaths. In comparable care homes in the same district, matched by age and socio-economic level, there was 22.6% COVID-19 and 5% death.

risk of death, 99.4% lower, RR 0.006, p = 0.08, treatment 0 of 69 (0.0%), control 150 of 3062 (4.9%), continuity correction due to zero event.

risk of COVID-19 case, 55.1% lower, RR 0.45, p = 0.01, treatment 7 of 69 (10.1%), control 692 of 3062 (22.6%).

Bernigaud et al., 11/28/2020, retrospective, France, Europe, peer-reviewed, 12 authors, dosage 200μg/kg days 1, 8, 15, 400μg/kg days 1, 8, 15, two different dosages.

Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248 (Peer Reviewed)

A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin

Analysis of COVID-19 cases vs. widespread prophylactic use of ivermectin for parasitic infections showing significantly lower incidence of COVID-19 cases.

risk of COVID-19 case, 78.0% lower, RR 0.22, p < 0.02, African countries, PCTI vs. no PCT, relative cases per capita.

risk of COVID-19 case, 80.0% lower, RR 0.20, p < 0.001, worldwide, PCTI vs. no PCT, relative cases per capita.

Hellwig et al., 11/28/2020, retrospective, ecological study, multiple countries, Africa, peer-reviewed, 2 authors, dosage 200μg/kg, dose varied, typically 150-200μg/kg.

Niaee et al., Research Square, doi:10.21203/rs.3.rs-109670/v1 (Preprint)

Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

82% lower mortality with ivermectin. RCT with 180 hospitalized patients showing reduced mortality and hospital stay with ivermectin, with a wide margin of safety. All patients received SOC including low dose HCQ.

risk of death, 81.8% lower, RR 0.18, p = 0.001, treatment 4 of 120 (3.3%), control 11 of 60 (18.3%), All IVM vs. all control.

risk of death, 94.3% lower, RR 0.06, p = 0.01, treatment 0 of 30 (0.0%), control 11 of 60 (18.3%), continuity correction due to zero event, IVM single dose 200mcg/kg vs. all control.

risk of death, 45.5% lower, RR 0.55, p = 0.37, treatment 3 of 30 (10.0%), control 11 of 60 (18.3%), IVM three dose 200mcg/kg vs. all control.

risk of death, 94.3% lower, RR 0.06, p = 0.01, treatment 0 of 30 (0.0%), control 11 of 60 (18.3%), continuity correction due to zero event, IVM single dose 400mcg/kg vs. all control.

risk of death, 81.8% lower, RR 0.18, p = 0.06, treatment 1 of 30 (3.3%), control 11 of 60 (18.3%), IVM three dose 400/200/200mcg/kg vs. all control.

Niaee et al., 11/24/2020, Double Blind Randomized Controlled Trial, Iran, Middle East, preprint, mean age 56.0, 14 authors, dosage 400μg/kg single dose, dose varies in different groups.

de Melo et al., bioRxiv, doi:10.1101/2020.11.21.392639 (Preprint)

Anti-COVID-19 efficacy of ivermectin in the golden hamster

Hamster study finding significantly lower COVID-19 pathology although not finding lower viral load at the dosage used. Ivermectin dramatically reduced the Il-6/Il-10 ratio in lung tissue, which may account for the more favorable clinical results.

de Melo et al., 11/22/2020, preprint, 11 authors.

Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223 (Preprint)

Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience

Retrospective 976 hospitalized patients with 34 treated with ivermectin showing ivermectin mortality relative risk RR 0.13, p = 0.04.

risk of death, 99.1% lower, RR 0.009, p = 0.04, treatment 0 of 34 (0.0%), control 103 of 942 (10.9%), continuity correction due to zero event.

Budhiraja et al., 11/18/2020, retrospective, India, South Asia, preprint, 12 authors, dosage not specified.

Carvallo et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007 (Peer Reviewed)

Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel

Prophylaxis study using ivermectin and iota-carrageenan showing 0 of 788 cases from treated healthcare workers, compared to 237 of 407 control.

The authors later reported that carrageenan is not necessary in this protocol [1].

[1] youtube.com/watch?v=CB6Bvi_g-w8

risk of COVID-19 case, 99.9% lower, RR 0.001, p < 0.001, treatment 0 of 788 (0.0%), control 237 of 407 (58.2%), continuity correction due to zero event.

Carvallo et al., 11/17/2020, prospective, Argentina, South America, peer-reviewed, 4 authors, dosage 12mg weekly, this trial uses multiple treatments in the treatment arm (combined with iota-carrageenan) - results of individual treatments may vary.

Spoorthi et al., IAIM, 2020, 7:10, 177-182 (Peer Reviewed)

Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2

100 patient prospective trial of ivermectin + doxycycline showing reduced time to symptom resolution and shorter hospital stay with treatment.

recovery time, 21.1% lower, relative time 0.79, p = 0.03, treatment 50, control 50.

hospitalization time, 15.5% lower, relative time 0.84, p = 0.01, treatment 50, control 50.

Spoorthi et al., 11/14/2020, prospective, India, South Asia, peer-reviewed, 2 authors, dosage not specified, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.

Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v2 (Preprint)

Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

RCT for prophylaxis with ivermectin showing a significant reduction in cases with treatment.

Relative risk of COVID-19 case RR 0.2, p = 0.03

This paper also reports a treatment study [1].

[1] c19study.com/elgazzar.html

risk of COVID-19 case, 80.0% lower, RR 0.20, p = 0.03, treatment 2 of 100 (2.0%), control 10 of 100 (10.0%).

Elgazzar et al., 11/13/2020, Randomized Controlled Trial, Egypt, Africa, preprint, 6 authors, dosage 400μg/kg weekly.

Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v2 (Preprint)

Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic

RCT comparing ivermectin + SOC vs. HCQ + SOC, showing a significant reduction in mortality with ivermectin. Mortality relative risk:

RR 0.11, p = 0.12 (mild/moderate cases)
RR 0.1, p < 0.001 (severe cases)

The HCQ dose is relatively low and may be too low to reach therapeutic levels. This paper also reports a prophylaxis study [1].

[1] c19study.com/elgazzarpep.html

risk of death, 91.7% lower, RR 0.08, p < 0.001, treatment 2 of 200 (1.0%), control 24 of 200 (12.0%).

risk of death, 88.9% lower, RR 0.11, p = 0.12, treatment 0 of 100 (0.0%), control 4 of 100 (4.0%), continuity correction due to zero event, mild/moderate COVID-19.

risk of death, 90.0% lower, RR 0.10, p < 0.001, treatment 2 of 100 (2.0%), control 20 of 100 (20.0%), severe COVID-19.

Elgazzar et al., 11/13/2020, Randomized Controlled Trial, Egypt, Africa, preprint, 6 authors, dosage 400μg/kg days 1-4, this trial compares with another treatment - results may be better when compared to placebo.

Camprubí et al., PLoS ONE, 15:11, doi:10.1371/journal.pone.0242184 (Peer Reviewed)

Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients

Tiny 26 patients retrospective study of ivermectin 200 μg/kg, median 12 days after symptoms, not showing significant differences. Authors suggest the dose is too low and recommend evaluation of higher doses.

All patients received HCQ which may reduce the potential benefit for adding ivermectin.

risk of ICU admission, 33.3% lower, RR 0.67, p = 1.00, treatment 2 of 13 (15.4%), control 3 of 13 (23.1%), ICU at day 8.

risk of no improvement at day 8, 33.3% higher, RR 1.33, p = 1.00, treatment 4 of 13 (30.8%), control 3 of 13 (23.1%).

Camprubí et al., 11/11/2020, retrospective, Spain, Europe, peer-reviewed, 9 authors, dosage 200μg/kg single dose.

Krolewiecki et al., SSRN (Preprint)

Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial

Viral load RCT finding a concentration dependent antiviral activity of oral high dose ivermectin at a dosing regimen that is well tolerated.

There was no significant difference in viral load reduction between groups overall, but a significant difference in reduction was found in patients with higher median plasma ivermectin levels (72% vs. 42%, p=0.004).

Decay rate was significantly greater in patients with higher median plasma ivermectin levels (0.64 vs. 0.13, p = 0.011).

Mean ivermectin plasma concentration levels showed a positive correlation with viral decay rate (r = 0.46, p = 0.02).

30 ivermectin patients and 15 control patients.

NCT004381884

Krolewiecki et al., 11/11/2020, preprint, 24 authors.

Turkia, M., ResearchGate (Review) (Preprint)

FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 — a brief review

Review suggesting that ivermectin should be used based on existing data suggesting significant benefits, and that waiting for additional data may result in significant harm.

Turkia et al., 11/10/2020, preprint, 1 author.

Cadegiani et al., medRxiv, doi:10.1101/2020.10.31.20223883 (Preprint)

Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

Comparison of HCQ, nitazoxanide, and ivermectin showing similar effectiveness for overall clinical outcomes in COVID-19 when used before seven days of symptoms, and overwhelmingly superior compared to the untreated COVID-19 population, even for those outcomes not influenced by placebo effect, at least when combined with azithromycin, and vitamin C, D and zinc in the majority of the cases.

585 patients with mean treatment delay 2.9 days. There was no hospitalization, mechanical ventilation, or mortality with treatment.

The size of the treatment groups in this trial can be found in [1].

[1] researchsquare.com/article/rs-98106/v1

risk of death, 78.3% lower, RR 0.22, p = 0.50, treatment 0 of 110 (0.0%), control 2 of 137 (1.5%), continuity correction due to zero event, control group 1.

risk of mechanical ventilation, 94.2% lower, RR 0.06, p = 0.005, treatment 0 of 110 (0.0%), control 9 of 137 (6.6%), continuity correction due to zero event, control group 1.

risk of hospitalization, 98.0% lower, RR 0.02, p < 0.001, treatment 0 of 110 (0.0%), control 27 of 137 (19.7%), continuity correction due to zero event, control group 1.

Cadegiani et al., 11/4/2020, prospective, Brazil, South America, preprint, 4 authors, dosage 200μg/kg days 1-3.

Morgenstern et al., J. Clinical Trials (preprint 11/3) (Peer Reviewed)

The Use of Compassionate Ivermectin in the Management of SymptomaticOutpatients and Hospitalized Patients with Clinical Diagnosis of Covid-19 at theCentro Medico Bournigal and at the Centro Medico Punta Cana, GrupoRescue, Dominican Republic, from May 1 to August 10, 2020

Retrospective 3,099 outpatients treated with ivermectin in an ER. Of 2,706 treated on an outpatient basis, 18 were subsequently hospitalized, 2 in the ICU, and there was one death (0.04%).

The average treatment delay for patients treated on an outpatient basis was 3.6 days, compared to 6.9 days for hospitalized patients, and 7.8 days for ICU patients.

For the 300 late treatment hospitalized patients there was 3 deaths. For the 111 very late treatment ICU patients there was 34 deaths.

Morgenstern et al., 11/3/2020, peer-reviewed, 14 authors.

Behera et al., PLoS ONE, doi:10.1371/journal.pone.0247163 (preprint 11/3) (Peer Reviewed)

Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study

Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.

HCQ OR 0.56, p = 0.29
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58

risk of COVID-19 case, 53.8% lower, RR 0.46, p < 0.001, treatment 41 of 117 (35.0%), control 145 of 255 (56.9%), adjusted, OR converted to RR, model 2 2+ doses conditional logistic regression.

risk of COVID-19 case, 44.5% lower, RR 0.56, p < 0.001, treatment 41 of 117 (35.0%), control 145 of 255 (56.9%), OR converted to RR, matched pair analysis.

Behera et al., 11/3/2020, retrospective, India, South Asia, peer-reviewed, 13 authors, dosage 300μg/kg days 1, 4.

Arévalo et al., Scientific Reports, doi:10.1038/s41598-021-86679-0 (preprint 11/2/20) (Peer Reviewed)

Ivermectin reduces in vivo coronavirus infection in a mouse experimental model

Mouse study showing ivermectin reducing MHV viral load and disease. MHV is a type 2 family RNA coronavirus similar to SARS-CoV2.

Arévalo et al., 11/2/2020, peer-reviewed, 12 authors.

Chang et al., ResearchGate (Preprint)

COVID-19: Effectiveness of pre-exposure prophylaxis with ivermectin in exposed persons

Pre-exposure prophylaxis study with 129 people split into high/low exposure groups, with each group split into different dosing regimens, showing higher effectivess with more frequent doses.

High-exposure group:

every 7 days dosing: 0 of 20 cases, 100% effective
every 14 days dosing: 1 of 47 cases, 98% effective
every 30 days dosing: 2 of 20 cases, 90% effective

Low-exposure group:

every 14 days dosing: 0 of 21 cases, 100% effective
every 30 days dosing: 1 of 20 cases, 95% effective

Chang et al., 10/31/2020, preprint, 2 authors.

Hashim et al., medRxiv, doi:10.1101/2020.10.26.20219345 (Preprint)

Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq

RCT 70 ivermectin+doxycycline patients and 70 control patients showing reduced time to recovery and reduced mortality with treatment.

The earlier ivermectin+doxycycline was administered, the higher rate of successful therapy.

risk of death, 66.7% lower, RR 0.33, p = 0.27, treatment 2 of 70 (2.9%), control 6 of 70 (8.6%), all patients.

risk of death, 91.7% lower, RR 0.08, p = 0.03, treatment 0 of 59 (0.0%), control 6 of 70 (8.6%), continuity correction due to zero event, excluding critical patients.

Hashim et al., 10/26/2020, Single Blind Randomized Controlled Trial, Iraq, Middle East, preprint, 6 authors, dosage 200μg/kg days 1-2, some patients received a third dose on day 8, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.

Guerrero et al., Colombia Médica, doi:10.25100/cm.v51i4.4613 (Peer Reviewed)

COVID-19: The Ivermectin African Enigma

Study of African Programme for Onchocerciasis Control (APOC) countries, which used ivermectin, with non-APOC countries in Africa, showing 28% lower mortality for APOC countries, relative risk RR = 0.72 [0.67-0.78]. See also [1] and the author's response [2].

[1] colombiamedica.univalle.edu.co/index.php/comedica/article/view/4816

[2] colombiamedica.univalle.edu.co/index.php/comedica/article/view/4833

Guerrero et al., 10/22/2020, peer-reviewed, 5 authors.

Carvallo et al., NCT04425850 (Preprint)

Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR)

Prophylaxis study using ivermectin and carrageenan showing 0 of 131 cases from treated healthcare workers, compared to 11 of 98 control.

The effect is likely to be primarily due to ivermectin - the author has later reported that carrageenan is not necessary [1].

[1] youtube.com/watch?v=CB6Bvi_g-w8

risk of COVID-19 case, 96.3% lower, RR 0.04, p < 0.001, treatment 0 of 131 (0.0%), control 11 of 98 (11.2%), continuity correction due to zero event.

Carvallo et al., 10/19/2020, prospective, Argentina, South America, preprint, 1 author, dosage 1mg days 1-14, this trial uses multiple treatments in the treatment arm (combined with iota-carrageenan) - results of individual treatments may vary.

Chaccour et al., Scientific Reports, doi:10.1038/s41598-020-74084-y (Peer Reviewed)

Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats

Study showing that nebulized ivermectin can reach pharmacodynamic concentrations in the lung tissue of rats. Authors note that additional experiments are required to assess the safety of this formulation in larger animals.

Chaccour et al., 10/13/2020, peer-reviewed, 8 authors.

Rajter et al., Chest, doi:10.1016/j.chest.2020.10.009 (Peer Reviewed)

Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study)

Retrospective 280 hospitalized patients showing lower mortality with ivermectin (13.3% vs 24.5%), propensity matched odds ratio OR 0.47 [0.22-0.99], p=0.045.

risk of death, 46.0% lower, RR 0.54, p = 0.04, treatment 13 of 98 (13.3%), control 24 of 98 (24.5%), adjusted, OR converted to RR, PSM.

risk of death, 66.9% lower, RR 0.33, p = 0.03, treatment 26 of 173 (15.0%), control 27 of 107 (25.2%), adjusted, OR converted to RR, multivariate.

Rajter et al., 10/13/2020, retrospective, USA, North America, peer-reviewed, 6 authors, dosage 200μg/kg single dose.

Mahmud et al., Clinical Trial Results, NCT04523831 (Preprint)

Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection

RCT for ivermectin+doxycycline showing improvements in mortality, recovery, progression, and virological cure. There is no paper yet, results are reported on clinicaltrials.gov. 183 treatment and 183 control patients with no deaths in the treatment arm vs. 3 in the control arm (the 3 control deaths are not included in the analysis of other outcomes). Treatment delay is not specified.

risk of death, 85.7% lower, RR 0.14, p = 0.25, treatment 0 of 183 (0.0%), control 3 of 183 (1.6%), continuity correction due to zero event.

risk of no recovery, 49.0% lower, RR 0.51, p < 0.004, treatment 42 of 183 (23.0%), control 67 of 180 (37.2%), adjusted.

risk of disease progression, 55.0% lower, RR 0.45, p < 0.01, treatment 16 of 183 (8.7%), control 32 of 180 (17.8%), adjusted.

risk of no virological cure, 42.0% lower, RR 0.58, p < 0.001, treatment 14 of 183 (7.7%), control 36 of 180 (20.0%), adjusted.

Mahmud et al., 10/9/2020, Double Blind Randomized Controlled Trial, Bangladesh, South Asia, preprint, 1 author, dosage 12mg single dose, this trial uses multiple treatments in the treatment arm (combined with doxycycline) - results of individual treatments may vary.

Francés-Monerris et al., ChemRxiv, doi:10.26434/chemrxiv.12782258.v1 (Preprint) (Theory)

Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent

In silico study showing that ivermectin is capable of interfering in different key steps of the SARS-CoV-2 replication cycle.

Francés-Monerris et al., 10/8/2020, preprint, 8 authors.

Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066 (Preprint)

Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru

Retrospective database study of 5683 patients, 692 received HCQ/CQ+AZ, 200 received HCQ/CQ, 203 received ivermectin, 1600 received AZ, 358 received ivermectin+AZ, and 2630 received standard of care.

This study includes anyone with ICD-10 COVID-19 codes which includes asymptomatic PCR+ patients, therefore many patients in the control group are likely asymptomatic with regards to SARS-CoV-2, but in the hospital for another reason. For those that had symptomatic COVID-19, there is also likely significant confounding by indication.

In this study all medications show higher mortality at day 30, which is consistent with asymptomatic (for COVID-19) or mild condition patients being more common in the control group.

For ivermectin they show 30 day mortality aHR = 1.39 [0.88 - 2.22]. KM curves show that the treatment groups were in more serious condition, and also that after about day 35 survival became better with ivermectin. The last day available for ivermectin shows RR 0.83, p = 0.01. More than the total excess mortality happened on the first day. This is consistent with treated patients being in more serious condition, and with many of the control group patients being in hospital for something unrelated to COVID-19.

Authors use a machine learning based propensity scoring system that appears over-parameterized and likely to result in significant overfitting and inaccurate results. Essentially they test for all interactions between two and three covariates. The nature and large number of covariates means many random correlations may be found. COVID-19 severity is not used.

This study also does not compare treatments with a control group not receiving the treatment - authors put patients receiving treatments after 48 hours in the control group.

Authors state that outcomes within 24 hours were excluded, however KM curves show significant mortality at day 1 (only for the treatment groups).

Several protocol violations and missing data have also been reported in this study: [1, 2].